Saeger Wolfgang, Lüdecke Dieter K, Buchfelder Michael, Fahlbusch Rudolf, Quabbe Hans-Jürgen, Petersenn Stephan
Institute of Pathology, Marienkrakenhaus, Alfredstrasse 9, D-22087 Hamburg, Germany.
Eur J Endocrinol. 2007 Feb;156(2):203-16. doi: 10.1530/eje.1.02326.
In 1996, the German Registry of Pituitary Tumors was founded by the Pituitary Section of the German Society of Endocrinology as a reference center for collection and consultant pathohistological studies of pituitary tumors. The experiences of the first 10 years of this registry based on 4122 cases will herein be reported. The data supplement former collections of the years 1970-1995 with 3480 surgically removed tumors or lesions of the pituitary region. The cases were studied using histology, immunostainings and in some cases also molecular pathology or electron microscopy. The adenomas were classified according to the current World Health Organization classification in the version of 2004. From 1996 on 3489 adenomas (84.6%), 5 pituitary carcinomas (0.12%), 133 craniopharyngiomas (3.2%), 39 meningiomas (0.94%), 25 metastases (0.6%), 22 chordomas (0.5%), 115 cystic non-neoplastic lesions (2.8%), and 46 inflammatory lesions (1.1%, 248 other lesions or normal tissue (6.0%)) were collected by us. The adenomas (100%) were classified into densely granulated GH cell adenomas (9.2%), sparsely granulated GH cell adenomas (6.3%), sparsely granulated prolactin (PRL) cell adenomas (8.9%), densely granulated PRL cell adenomas (0.3%), mixed GH/PRL cell adenomas (5.2%), mammosomatotropic adenomas (1.1%), acidophilic stem cell adenomas (0.2%), densely granulated ACTH cell adenomas (7.2%), sparsely granulated ACTH cell adenomas (7.9%), Crooke cell adenomas (0.03%), TSH cell adenomas (1.5%), FSH/LH cell adenomas (24.8%), null cell adenomas (19.3%), null cell adenoma, oncocytic variant (5.8%), and plurihormonal adenomas (1.3%). Following the WHO classification of 2004, the new entity 'atypical adenoma' was found in 12 cases in 2005. Various prognostic parameters and clinical implications are discussed.
1996年,德国内分泌学会垂体分会创立了德国垂体肿瘤登记处,作为垂体肿瘤病理组织学研究的收集和咨询中心。本文将报告该登记处头10年基于4122例病例的经验。这些数据补充了1970 - 1995年期间收集的3480例手术切除的垂体区域肿瘤或病变。对这些病例进行了组织学、免疫染色研究,部分病例还进行了分子病理学或电子显微镜检查。腺瘤根据2004年版的世界卫生组织现行分类进行分类。从1996年起,我们收集了3489例腺瘤(84.6%)、5例垂体癌(0.12%)、133例颅咽管瘤(3.2%)、39例脑膜瘤(0.94%)、25例转移瘤(0.6%)、22例脊索瘤(0.5%)、115例囊性非肿瘤性病变(2.8%)以及46例炎性病变(1.1%)、248例其他病变或正常组织(6.0%)。腺瘤(100%)分为密集颗粒型生长激素(GH)细胞腺瘤(9.2%)、稀疏颗粒型GH细胞腺瘤(6.3%)、稀疏颗粒型催乳素(PRL)细胞腺瘤(8.9%)、密集颗粒型PRL细胞腺瘤(0.3%)、混合性GH/PRL细胞腺瘤(5.2%)、促乳腺生长激素腺瘤(1.1%)、嗜酸性干细胞腺瘤(0.2%)、密集颗粒型促肾上腺皮质激素(ACTH)细胞腺瘤(7.2%)、稀疏颗粒型ACTH细胞腺瘤(7.9%)、克鲁克细胞腺瘤(0.03%)、促甲状腺激素(TSH)细胞腺瘤(1.5%)、促卵泡激素/促黄体生成素(FSH/LH)细胞腺瘤(24.8%)、无功能细胞腺瘤(19.3%)、无功能细胞腺瘤嗜酸性变(5.8%)以及多激素腺瘤(1.3%)。按照2004年世界卫生组织分类,2005年发现了12例新的实体“非典型腺瘤”。文中还讨论了各种预后参数及临床意义相关内容。